Becton, Dickinson and Company (BDX)

Executive Summary / Key Takeaways

• Pure-Play MedTech Inflection: The February 2026 Waters spin-off transforms BDX into a focused medical technology company with over 90% of revenue from recurring consumables, a dramatically simplified manufacturing footprint (under 50 sites vs. over 90 previously), and leading positions in more than 90% of its markets—creating a structurally higher-quality earnings stream.

• Margin Expansion Despite Headwinds: BD Excellence delivered 8% productivity improvements in Q1 2026 and has executed 75% of a $200 million cost-out program, driving gross margins to 53.4% while absorbing approximately 170 basis points of tariff impact—demonstrating operational leverage that will become more visible as FY26 transition costs roll off.

• Transition Year Masking Underlying Strength: FY26 guidance reflects 250 basis points of headwinds from Alaris remediation completion, China volume-based procurement, and vaccine softness—yet the remaining 90% of the portfolio is delivering mid-single-digit growth, with double-digit expansion in GLP-1 delivery, PureWick, advanced tissue regeneration, and pharmacy automation.

• Valuation Disconnect Creates Opportunity: Management states New BD trades at approximately 10x earnings while Waters fetches nearly 20x, embedding roughly $50 per share in Waters value within BDX's current $154 stock price—leaving the core MedTech business priced for minimal growth despite high-single-digit earnings potential post-tariffs.

• Capital Allocation Accelerates Compounding: The $4 billion Waters cash distribution, with $2 billion earmarked for share repurchases via an ASR program and $2 billion for debt reduction, will boost New BD's EPS growth by over 200 basis points while management continues to view buybacks as value-creating at current levels.

Setting the Scene: From Syringes to Smart Connected Care

Becton, Dickinson and Company, founded in 1897 and headquartered in Franklin Lakes, New Jersey, has spent 128 years building what is arguably the most foundational medical device infrastructure on the planet. The company manufactures over 35 billion devices annually, reaching healthcare providers in more than 190 countries. For most of its history, BD was synonymous with medical supplies—syringes, needles, and basic specimen collection. But the past decade has been a deliberate transformation guided by three irreversible healthcare trends: the rise of smart connected devices, robotics, AI, and informatics; the shift of care toward lower-cost settings; and explosive growth in chronic disease technologies.

This transformation accelerated through strategic portfolio shaping. BD divested three substantial non-core assets, including its diabetes business, while completing over 20 tuck-in acquisitions such as Parata pharmacy automation and Advanced Patient Monitoring. The February 9, 2026 completion of the Waters transaction—spinning off Biosciences and Diagnostic Solutions via a Reverse Morris Trust —represents the culmination of this strategy. The "New BD" emerges as a pure-play MedTech leader with over 90% recurring consumables revenue, a manufacturing network reduced from over 90 global sites to under 50, and a simplified structure that eliminates the complexity that had historically masked its earnings power.

BD's position in the value chain is unique: it sits at the intersection of drug delivery, infection prevention, and clinical workflow automation. Unlike pure-play device competitors like Medtronic (MDT) that focus on high-value implants, or life sciences tool companies like Thermo Fisher (TMO) that serve research labs, BD's portfolio addresses the daily operational realities of healthcare delivery. This creates a defensive moat rooted in habit, regulation, and clinical standard-of-care—hospitals don't switch IV catheter suppliers lightly when patient safety is at stake.

The competitive landscape reveals both strengths and vulnerabilities. Against TMO's high-throughput research tools, BD offers clinically oriented, cost-effective solutions that win on reliability and integration. Versus MDT's premium interventional devices, BD competes on scale and accessibility, particularly in emerging markets. Abbott (ABT) outpaces BD in point-of-care diagnostic speed, while Danaher (DHR) commands higher operating margins through its acquisition-driven efficiency model. Yet none match BD's combination of manufacturing scale (28 U.S. plants producing over 10 billion devices), regulatory expertise forged through 125 years of FDA interactions, and the trust embedded in clinical workflows.

Technology, Products, and Strategic Differentiation: The GLP-1 Goldmine and Connected Care Platform

BD's technological moat isn't built on breakthrough science alone, but on the integration of safety, reliability, and scale into products that become industry standards. The BioPharma Systems segment exemplifies this with its prefillable drug delivery systems, where BD has captured over 80 novel and biosimilar GLP-1 molecules in its devices. This is significant because biologics now represent 50% of total Pharma Systems sales, and the GLP-1 market is expanding at a pace that could make this franchise a $1 billion revenue stream by decade's end. Pharmaceutical companies need proven, scalable delivery systems for complex biologics, and BD's manufacturing quality and regulatory track record create switching costs that lock in multi-year contracts. Each new molecule contracted represents not just revenue, but a deepening of BD's integration into the drug development lifecycle.

The Connected Care segment showcases BD's evolution from commodity devices to smart, connected platforms. The Pyxis Pro medication dispensing system—an AI-powered platform that feeds data into the new Incada AI platform—has achieved 85% of initial orders from competitive conversions. This is a fundamental shift where BD is displacing entrenched competitors by offering not just hardware, but an intelligent system that transforms nurse workflow and drug availability. Alaris infusion pumps, after years of regulatory remediation, delivered their strongest quarter of competitive wins since relaunch, increasing category share by approximately 100 basis points. This validates that the consent decree remediation hasn't permanently impaired the brand and demonstrates that BD's sales force can execute on competitive takeaways.

Advanced Patient Monitoring (APM) grew high single digits in Q1, with HemoSphere Stream—a continuous noninvasive blood pressure monitoring module—beginning targeted release in the U.S. and Europe. Management expects smart cable compatibility to expand its addressable market tenfold. This moves BD from episodic monitoring to continuous data streams, creating higher consumables attach rates and positioning the company to capture value from the shift toward value-based care that rewards outcome improvement.

BD Excellence, the company's operating system, has reduced manufacturing waste by over 35% and increased Overall Equipment Effectiveness (OEE) significantly, creating capacity for an additional 2.5 billion units on existing production lines. In Q1 2026 alone, it delivered 8% productivity improvements. This is a structural expansion of manufacturing capacity without capital expenditure, directly improving gross margins and freeing cash for reinvestment in high-growth areas like APM and GLP-1 delivery.

Financial Performance & Segment Dynamics: Margin Resilience in a Transition Year

First quarter fiscal 2026 results reveal a company managing through deliberate headwinds while building underlying strength. Total revenues increased 1.6% as reported and 0.4% on an FX-neutral basis, but New BD revenue excluding the divested Life Sciences business grew 2.5% FX-neutral—already at the full-year run rate management targeted. Adjusted gross margin of 53.4% and adjusted EPS of $2.91 both exceeded expectations, demonstrating that tariff impacts of approximately 170 basis points are being partially offset by BD Excellence productivity initiatives.

Segment performance tells a story of selective pressure and broad-based strength. Medical Essentials revenue of $1.595 billion grew just 0.6% FX-neutral, reflecting expected order timing dynamics and Volume-Based Procurement (VBP) impacts in China. The operating margin decline from 38.3% to 35.6% was driven by higher labor costs, tariff impacts, and unfavorable FX—partially mitigated by lower manufacturing costs from continuous improvement. This segment's stability is vital as it represents BD's foundation: vascular access management share gains in the U.S. offset China headwinds, proving the portfolio's resilience even as 20% of the business faces pricing pressure.

Connected Care delivered 4.7% FX-neutral growth to $1.131 billion, with Pharmacy Automation (BD Rowa) and strong infusion set sales driving momentum. The segment's operating margin held steady at 31.1% despite tariff headwinds, reflecting favorable product mix and manufacturing productivity. This stability shows BD can invest in next-generation platforms like Pyxis Pro without sacrificing profitability, positioning the segment for accelerated growth as these platforms scale.

BioPharma Systems grew 1.0% FX-neutral to $429 million, but the underlying story is far stronger. U.S. prefillable solutions for biologic drugs grew double digits, led by GLP-1 delivery products, while vaccine demand declined. With biologics now 50% of Pharma Systems sales and over 80 GLP-1 molecules contracted, this segment is undergoing a mix shift that will drive higher margins and more predictable revenue.

Interventional was the standout performer, with 5.1% FX-neutral growth to $1.330 billion and operating margins of 42.1%—the highest in the portfolio. Peripheral Intervention's oncology products and Rotarex Atherectomy System drove strong U.S. sales, while Urology and Critical Care's PureWick offerings delivered double-digit growth. Surgery achieved double-digit growth in advanced tissue regeneration and high single-digit growth in infection prevention, with new market entries expanding served markets by over $550 million.

Life Sciences declined 10.5% FX-neutral to $766 million, reflecting lower U.S. point-of-care sales and reduced Biosciences instrument sales due to research funding pressures. Operating margins compressed from 28.7% to 20.8% due to revenue deleverage and higher R&D spending. While this segment's separation removes a drag on growth, its historical performance illustrates why the Waters transaction was necessary.

Cash flow generation remains robust, with $657 million from operating activities in Q1 2026 and $549 million in free cash flow. The company returned $549 million to shareholders through $299 million in dividends and $250 million in share repurchases, while maintaining net leverage at 2.9x with a long-term target of 2.5x. The $1.17 billion in commercial paper borrowings and $2.75 billion undrawn revolving credit facility provide ample liquidity to execute the $2 billion ASR program in Q2 2026. This capital allocation signals management's confidence that the stock trades below intrinsic value.

Outlook, Management Guidance, and Execution Risk

Management's FY26 guidance reflects a prudent approach designed to clear the table on macro dynamics and eliminate the back-half ramps that affected prior years. New BD revenue growth is expected in the low single digits, with adjusted EPS of $12.35 to $12.65 representing approximately 6% growth at the midpoint. The guidance includes a 370 basis point tariff impact—meaning operational earnings growth would be high single digits absent trade pressures. This sets a conservative baseline that doesn't require macro improvement for achievement.

The guidance quantifies three headwinds affecting approximately 10% of revenue: Alaris capital installations create a 100+ basis point headwind as FY25's record install levels create tough comparisons; China VBP drives a mid-teens decline, impacting growth by about 100 basis points; and vaccine ordering patterns decline approximately 25%, hitting growth by 50 basis points. The combined 250 basis point drag is offset by mid-single-digit growth in the remaining 90% of the portfolio. This segmentation isolates temporary, cyclical pressures from the core business's durable growth engine.

Management's commentary on phasing is instructive. Q2 2026 revenue is expected at approximately 2%, consistent with the full-year run rate, with no ramp from the first half to the second half. This represents a structural improvement in guidance quality, removing the execution risk of assumed back-half acceleration. The implication is that BD's business has become more predictable, with growth drivers like GLP-1 momentum and APM expansion providing steady contributions.

Longer-term, management is confident in delivering overall mid-single-digit growth as these dynamics exit. Alaris is expected to step up to a 200 basis point headwind in FY27 before normalizing, while China VBP is projected to reach 80% portfolio coverage by FY26 end, after which pricing pressure should abate. The GLP-1 franchise is tracking toward $1 billion by decade's end, with oral formulations seen as complementary rather than disruptive to injectables.

Risks and Asymmetries: What Could Break the Thesis

The most material risk to the investment case is execution failure in China, where VBP programs and healthcare practitioner compliance initiatives are driving a mid-teens revenue decline. Management assumes VBP will reach 80% coverage by FY26 end, but further expansion or more aggressive price cuts could extend the headwind beyond 2027. China represents a meaningful portion of emerging market growth, and failure to stabilize this business would impact BD's geographic diversification strategy.

Alaris regulatory risk remains tangible despite recent progress. The FDA consent decree authorizes the agency to order manufacturing cessation, recalls, and significant monetary damages for future violations. While BD received 510(k) clearance in July 2023 and April 2025, and remediation is expected to be substantially complete by calendar 2026 end, any new compliance issues could restart the clock.

Legal and environmental liabilities create additional overhang. BD faces 6,905 hernia repair device claims, 2,765 implantable port claims with trials scheduled for 2026, and approximately 420 lawsuits alleging injury from ethylene oxide (EtO) sterilization. While management has accrued $83 million for the FDA Warning Letter regarding its Dispensing quality management system, these liabilities could exceed current reserves.

Tariff impacts remain a persistent headwind. The full-year FY26 tariff impact is anticipated at $275 million, with approximately 170 basis points hitting Q1 gross margins. BD has mitigated through supply flow shifts and supplier location optimization, but the ultimate impact depends on duration and rate changes.

On the positive side, the primary upside asymmetry lies in GLP-1 market expansion. With over 80 molecules contracted and biologics representing 50% of Pharma Systems sales, BD is positioned to capture a share of the obesity and diabetes treatment wave. Additionally, the Incada AI platform and connected care ecosystem could create data-driven revenue streams not currently modeled, potentially transforming BD from a device manufacturer into a healthcare informatics company.

Valuation Context: A MedTech Leader Priced Like a Laggard

At $154.13 per share, BDX trades at 25.18 times trailing earnings and 12.35 times EV/EBITDA. These multiples mask a significant valuation disconnect. The Waters transaction embedded approximately $50 per share of value based on the current share price and BD's 39.2% ownership, meaning the remaining New BD business trades at roughly 10x earnings—a multiple typically associated with slow-growth industrial companies, not a market leader with 90% recurring revenue.

Peer comparisons reveal the gap. Thermo Fisher trades at 18.63x EV/EBITDA with 21.17% operating margins. Medtronic commands 13.80x EV/EBITDA with 65.16% gross margins. Abbott trades at 15.66x EV/EBITDA with 56.66% gross margins. Danaher, at 19.01x EV/EBITDA, shows how the market rewards operational excellence. BDX's 46.78% gross margin and 13.35% operating margin reflect the inclusion of the lower-margin Life Sciences business that has now been separated. New BD's pro forma margins are expected to be in the mid-20s, comparable to peers.

The company's capital structure supports valuation expansion. With net leverage at 2.9x and a target of 2.5x, BD has room to optimize its balance sheet. The $2 billion debt paydown from Waters proceeds will reduce interest expense, while the $2 billion ASR program will reduce share count by approximately 7% at current prices. This combination is expected to boost New BD's EPS growth by over 200 basis points.

BD's 2.72% dividend yield and 68% payout ratio provide downside protection, while the 0.31 beta indicates low correlation to market volatility. The company's commitment to returning $2.2 billion to shareholders in FY25, including $1 billion in buybacks, demonstrates a shareholder-friendly capital allocation policy. BDX offers a combination of dividend yield, buyback support, and earnings growth potential at a multiple that does not require heroic assumptions.

Conclusion: A Transition Story Worth Owning

Becton Dickinson's transformation from a diversified healthcare conglomerate into a focused MedTech pure-play represents a compelling risk/reward setup in large-cap healthcare. The Waters spin-off has created a simpler, higher-quality business with over 90% recurring revenue, leading market positions, and a manufacturing network optimized for efficiency. While FY26 guidance reflects 250 basis points of temporary headwinds from Alaris remediation completion, China VBP, and vaccine softness, the underlying 90% of the portfolio is delivering mid-single-digit growth with expanding margins.

The investment thesis hinges on three factors: First, BD Excellence's productivity gains are structural, creating permanent margin expansion that will become more visible as tariff impacts normalize. Second, the GLP-1 delivery franchise and connected care platforms provide durable growth engines. Third, the valuation disconnect—New BD trading at approximately 10x earnings while peers command 15-20x—creates significant re-rating potential.

The primary risks are execution-related: China VBP could prove more persistent than modeled, Alaris could face new regulatory setbacks, or legal liabilities could exceed reserves. However, management's prudent guidance framework, strong cash generation, and proactive capital allocation mitigate these concerns. The $4 billion Waters proceeds being deployed into accretive buybacks and debt reduction will accelerate EPS growth and demonstrate management's conviction in the intrinsic value.

For investors willing to look through the FY26 transition noise, BDX offers a rare combination: a 125-year-old market leader with improving fundamentals, a shareholder-friendly capital return program, and a valuation that prices in minimal growth just as the business is poised to accelerate. If successful, the current 10x multiple on New BD earnings could expand toward the 15-18x range enjoyed by peers, implying significant upside on multiple expansion alone.